Full-Time

Senior Manager/Associate Director

GMP Quality Assurance

Posted on 7/10/2025

Orbital Therapeutics

Orbital Therapeutics

11-50 employees

RNA-based medicines development and delivery platform

Compensation Overview

$134k - $210k/yr

Cambridge, MA, USA

In Person

Category
QA & Testing (1)
Required Skills
Google Cloud Platform
Requirements
  • B.S. or M.S. in a scientific discipline
  • 6–8 years of biopharma experience, with at least 4 years of GMP QA experience in a manufacturing/CMC setting
  • Experience with batch record review
  • Vendor management experience
  • Quality Management System experience, with Veeva strongly preferred
  • Familiarity with FDA and EU GMP regulations
  • GCP/GLP exposure is a plus
  • Hands-on, detail-oriented, with the ability to thrive in a lean, fast-paced biotech
  • Strong communication and interpersonal skills for effective cross-functional collaboration
Responsibilities
  • Serve as the primary internal GMP Quality Assurance lead, ensuring compliance with FDA, EU, and other regulatory authorities
  • Manage and maintain Orbital’s electronic Quality Management System (Veeva), including change controls, deviations, and Corrective and Preventive Actions
  • Conduct detailed technical review of GMP manufacturing batch records, validation reports, stability data, and product release documentation
  • Oversee vendor quality, including contract manufacturers, through audits, quality agreements, and issue resolution
  • Support qualification of contract manufacturing/testing sites and distribution depots
  • Participate in audits (domestic and international) to assess compliance status and mitigate risks
  • Collaborate cross-functionally with Chemistry, Manufacturing and Controls and Regulatory teams to ensure timely, accurate quality deliverables
  • Provide input into long-term quality strategy, with an initial focus on GMP and an opportunity for future growth into GCP/GLP oversight
Desired Qualifications
  • RNA/Lipid Nanoparticle product experience strongly preferred
  • GCP/GLP exposure a plus
  • Experience with quality metrics and data analytics in a GMP environment
  • Experience with vendor quality assurance and inspection readiness
  • Regulatory affairs knowledge related to quality systems in Biopharma

Orbital Therapeutics creates RNA-based medicines (not including siRNA) and builds a platform that combines RNA design, delivery methods, data science, and automation to develop a wide range of therapies. Its initial focus areas are vaccines, immunomodulation, and protein replacement. The company develops and commercializes RNA medicines, selling them to healthcare providers who administer treatment to patients. It differentiates itself through an integrated platform that merges RNA technology with delivery and automated data-driven workflows to accelerate discovery and development. Led by experts in genetic medicine, including Dr. Giuseppe Ciaramella, the team leverages deep experience in antivirals, immunology, and biotherapeutics to guide research. The goal is to improve global health by making RNA medicines accessible for diseases previously difficult to treat.

Company Size

11-50

Company Stage

Acquired

Total Funding

$1.8B

Headquarters

San Francisco, California

Founded

2022

Simplify Jobs

Simplify's Take

What believers are saying

  • Bristol Myers Squibb acquires Orbital for $1.5 billion, validating platform.
  • OTX-201 shows full B cell depletion in non-human primates per July 2025 data.
  • Plans IND filing and clinical trials for OTX-201 in first half 2026.

What critics are saying

  • OTX-201 fails Phase 1/2 trials due to human efficacy mismatches in 18-36 months.
  • BMS integration causes CEO Ron Philip departure, disrupting expertise in 12-24 months.
  • FDA delays OTX-201 IND beyond H1 2026 over circular RNA regulatory uncertainty.

What makes Orbital Therapeutics unique

  • Orbital pioneers circular RNA for in vivo CAR-T therapy OTX-201 targeting CD19.
  • Platform integrates RNA design, targeted LNPs, and AI for immune reprogramming.
  • Focuses on autoimmune diseases via B cell depletion and immune reset.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Growth & Insights and Company News

Headcount

6 month growth

6%

1 year growth

18%

2 year growth

23%
Bristol Myers Squibb
Oct 14th, 2025
Bristol Myers Squibb Strengthens and Diversifies Cell Therapy Portfolio with Acquisition of Orbital Therapeutics

Acquisition includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogram cells in vivo with potential best-in-class profile for autoimmune diseases Transaction further strengthens BMS’s industry-leading cell therapy portfolio, expanding CAR T-cell access to more patients in the future Bristol Myers Squibb (NYSE: BMY, “BMS”) and Orbital Therapeutics (“Orbital”) today announced a definitive agreement under which BMS will acquire Orbital, a privately held biotechnology company pioneering a new generation of RNA medicines that reprogram the immune system in vivo , enabling treatments that provide the precision, control, and flexibility needed to address the underlying biology and unique complexities of each disease. “ In vivo CAR T represents a novel treatment approach that could redefine how we treat autoimmune diseases,” said Robert Plenge, MD, PhD, executive vice president, Chief Research Officer, BMS. “This acquisition enhances our robust cell therapy

Global Legal Group
Oct 13th, 2025
Covington aids Bristol Myers Squibb on Orbital Therapeutics acquisition

International law firm Covington & Burling LLP has advised multinational biopharmaceutical company Bristol Myers Squibb in its definitive agreement to acquire biotech company Orbital Therapeutics.

Pharmaceutical Executive
Oct 11th, 2025
Bristol Myers Squibb Enters $1.5 Billion Definitive Agreement Acquiring Orbital Therapeutics

"Since inception, Orbital has made significant strides developing a differentiated RNA platform designed to enable a new generation of RNA medicines that reach more tissues, address more diseases, and benefit more patients.

PMLiVE
Sep 8th, 2025
Adam Raff appointed as Orbital Therapeutics' Senior Vice President, Clinical Development

Orbital Therapeutics, a biotechnology company pioneering a new generation of RNA medicines that reprogramme the immune system in vivo to treat disease at its source, have appointed Adam Raff, as Senior Vice President, Clinical Development.

Pipeline Review
Jul 22nd, 2025
Orbital Therapeutics Presents Non-Human Primate Data for In Vivo CAR-T Therapy with Potential Best-in-Class Profile for Autoimmune Disease

Orbital is developing OTX-201 for B cell-driven autoimmune diseases, where the therapeutic goal is to deplete autoreactive B cells and reset the immune system.

INACTIVE